| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e065dc5a00171bedf8adadadcef6da83 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M31-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2020-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b417d40aa9c816c16392338ecbb3175b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_409e504bb952aa1a883a19343d35dc59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7a6d51515a0bfa5ca8e50151c51a587
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52d3af2a0875d7c662dbbbf6a5dc5883 |
| publicationDate |
2020-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2020267162-A1 |
| titleOfInvention |
Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| abstract |
An intranasal testosterone gel for topical administration into a nasal cavity to control release of ntestosterone over a period of at least about 6 hours following the nasal cavity administration to nprovide replacement or supplemental testosterone in a male or female for treating male or female ntestosterone deficiency, without causing an unacceptable spike in testosterone blood level over dose nlife, said intranasal testosterone gel comprising: (a) testosterone in an amount effective to treat nmale/female testosterone deficiency; (b) at least one lipophilic or partly lipophilic carrier; (c) a super nsolvent for increasing testosterone solubility in said intranasal testosterone gel; and (d) a viscosity nregulating agent in an amount effective to control the release of said testosterone from said intranasal ntestosterone gel, wherein said intranasal testosterone gel does not need a surfactant. nAn applicator system for perinasal administration testosterone gel (a) a chamber pre-filled with the nplurality of doses of the testosterone gel; (b) an actuator nozzle, said actuator nozzle comprising an noutlet channel and a tip and having a shape that conforms to the interior surface within the nasal ncavity.nWO 2012/156822 PCT/IB2012/001127 n1/29 n134 n130 n102 n132 n100 n144 n128 n150 n126 n122 n120 n.124 nFIG. 1 |
| priorityDate |
2011-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |